Successful Drug Discovery
Wiley-VCH (Verlag)
978-3-527-34754-4 (ISBN)
- Einmalig: Dieses Fachbuch legt den Schwerpunkt auf erst kürzlich eingeführte Arzneimittel, die bislang noch nicht in Lehrbüchern und allgemeinen Referenzwerken behandelt werden. Die Informationen und Erkenntnisse sind in jeder Hinsicht neu und häufig noch nicht einmal in der Primärliteratur zu finden.
- Von den Besten des Fachgebiets lernen: Erfolgreiche Arzneimittelentwickler aus Industrie, Forschung und Lehre zeigen, wie man Arzneistoffe bis zur Markteinführung erfolgreich entwickelt.
- Unterstützt von IUPAC: Die International Union of Pure and Applied Chemistry (Internationale Union für reine und angewandte Chemie) als die weltweite Vereinigung in der Chemie unterstützt und fördert das Projekt aufgrund seines hohen Verdienstes um die Ausbildung junger medizinischer Chemiker.
Following the successful approach of the previous volumes in the series, the inventors and primary developers of drugs that made it to the market tell the story of the drug's discovery and development and discuss the sometimes twisted route from the first drug candidate molecule to the final marketed drug. After a general section that addresses overarching topics for drug discovery, 8 selected case studies of individual drugs or drug classes describe recently introduced drugs, encompassing small molecules, antibodies and oligonucleotides, thereby providing a representative cross-section of the present-day drug development effort. Backed up by lots of data and chemical information, the insight and experience of the best contemporary drug creators turns this book into one of the most useful training manuals that a junior medicinal chemist can hope to find.
Janos Fischer is a Senior Research Scientist at Richter Plc., Budapest, Hungary. He received his MSc and PhD degrees in organic chemistry from the Eotvos University of Budapest. He has worked at Richter Plc. since 1981 where he participated in the research and development of leading cardiovascular drugs in Hungary. His main interest is analogue based drug discovery. He is the author of some 100 patents and scientific publications. Since 2014 he is Chair of the Subcommittee on Drug Discovery and Development of IUPAC. He received an honorary professorship at the Technical University of Budapest.
Christian Klein is Head of Oncology Programs at the Roche Innovation Center Zurich, specialized in the discovery, validation and preclinical development of antibody based cancer immunotherapies and bispecific antibodies. During his 15 years at Roche he has made major contributions as research project leader to the development and FDA/EMA approval of obinutuzumab, the preclinical development of four bispecific antibodies currently in active clinical development, as well as the development of Roche's novel proprietary bispecific antibody platforms e.g. the CrossMAb technology.
Wayne Childers is Associate Professor of Pharmaceutical Sciences at Temple University, Philadelphia, USA. He received his academic degrees from Vanderbilt University and from the University of Georgia. He served as an assistant adjunct professor at Bucknell University before accepting a position as a postdoctoral fellow at the Johns Hopkins University School of Medicine. He then joined Wyeth, working in numerous therapeutic areas, including psychiatric diseases, stroke, and Alzheimer's disease, and the treatment of chronic pain. He stayed with Wyeth for 22 years, before joining the faculty of Temple University in 2010.
PART I: GENERAL ASPECTS
Drug Discovery in Academia
From Degraders to Molecular Glues - New Ways of Breaking Down Disease-Associated Proteins
PART II: DRUG CLASS STUDIES
GLP-1 Receptor Agonists for the Treatment of Type-2 Diabetes and Obesity
Recent advances on SGLT2 inhibitors: Synthetic approaches, therapeutic benefits and adverse events
CAR T cells - a Novel Biological Drug Class
CGRP-Inhibitors for the Treatment of Migraine
PART III: CASE STUDIES
Discovery and Development of Emicizumab (HEMLIBRA), a humanized bispecific antibody to coagulation factors IXa and X with a factor VIII cofactor activity
Discovery and Development of Ivosidenib (AG-120; TIBSOVO)
The discovery of Kisqali (ribociclib), a CDK4/6 inhibitor for the treatment of HR positive/HER2 negative advanced breast cancer
| Erscheinungsdatum | 11.03.2021 |
|---|---|
| Verlagsort | Weinheim |
| Sprache | englisch |
| Maße | 170 x 244 mm |
| Gewicht | 762 g |
| Einbandart | gebunden |
| Themenwelt | Medizin / Pharmazie ► Pharmazie |
| Naturwissenschaften ► Biologie ► Biochemie | |
| Naturwissenschaften ► Chemie | |
| Schlagworte | Chemie • Chemistry • Drug Discovery & Development • Medical Science • Medizin • Organic Chemistry • Organische Chemie • Pharmacology & Pharmaceutical Medicine • Pharmakologie • Pharmakologie u. Pharmazeutische Medizin • Wirkstoffforschung • Wirkstoffforschung u. -entwicklung |
| ISBN-10 | 3-527-34754-2 / 3527347542 |
| ISBN-13 | 978-3-527-34754-4 / 9783527347544 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
